Neglected tropical diseases: Now more than just 'other diseases'- the post-2015 agenda

International Health

Volumn 6, Issue 3, 2014, Pages 172-180

  Molyneux, David H ^a  

^a LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

Author keywords

Disease control; Disease elimination; Millennium development goals; Neglected tropical diseases

Indexed keywords

APPLIED RESEARCH; ARTICLE; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; DISEASE ELIMINATION; DISEASE ERADICATION; DOG; DRACUNCULIASIS; DRUG INDUSTRY; ECONOMIC DEVELOPMENT; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH PROGRAM; HUMAN; INVESTMENT; MEDICATION COMPLIANCE; MONEY; NEGLECTED DISEASE; NEGLECTED TROPICAL DISEASE; NONHUMAN; PATIENT ADVOCACY; PHARMACEUTICAL CARE; PHASE 2 CLINICAL TRIAL (TOPIC); RESEARCH PRIORITY; SOCIAL EVOLUTION; SYSTEM ANALYSIS; TROPICAL DISEASE; UNITED KINGDOM; WORLD HEALTH ORGANIZATION; COST OF ILLNESS; ECONOMICS; FINANCIAL MANAGEMENT; HEALTH; HEALTH CARE DELIVERY; NEGLECTED DISEASES; ORGANIZATION AND MANAGEMENT; PROCEDURES; TROPICAL MEDICINE;

COST OF ILLNESS; DELIVERY OF HEALTH CARE; FINANCING, ORGANIZED; GLOBAL HEALTH; HEALTH POLICY; HEALTH SERVICES ACCESSIBILITY; HUMANS; NEGLECTED DISEASES; TROPICAL MEDICINE;

EID: 84907442986     PISSN: 18763413     EISSN: 18763405     Source Type: Journal    
DOI: 10.1093/inthealth/ihu037     Document Type: Article

References (89)

1. Molyneux DH. Neglected diseases but unrecognised successes: challenges and opportunities for infectious disease control. Lancet 2004;364:380-3.
2. Molyneux DH, Hotez PJ, Fenwick A. "Rapid-impact interventions": how a policy of integrated control for Africa's neglected tropical diseases could benefit the poor. PLoS Med 2005;2:e336. Epub 2005 Oct 11.
3. Hotez PJ, Molyneux DH, Fenwick A et al. Incorporating a rapid-impact package for neglected tropical diseases with programs for HIV/AIDS, tuberculosis, and malaria. A comprehensive pro-poor health policy and strategy for the developing world. PLoS Med 2006;3:e102.
4. Hotez PJ, Fenwick A, Savioli L, Molyneux DH. Rescuing the bottom billion through control of neglected tropical diseases. Lancet 2009;373:1570-5.
5. Molyneux DH. Combating the "other diseases" of MDG 6: changing the paradigm to achieve equity and poverty reduction? Trans R Soc Trop Med Hyg 2008:102:509-19.
6. WHO. First global report on neglected tropical diseases 2010. Geneva: World Health Organization; 2010.
7. WHO. Sustaining the drive to overcome the global impact of neglected tropical diseases. Second global report. Geneva: World Health Organization; 2013.
8. WHO. Intensified control of neglected diseases: report of an international workshop, Berlin, 10-12 December 2003. Geneva: World Health Organization; 2004.
9. WHO. Intensified control of neglected diseases: report of an international workshop, Berlin, April 2005. Geneva: World Health Organization; 2005.
10. Commission for Africa. Our common interest: Report for the Commission of Africa. March 2005. Commission for Africa; 2005.
11. WHO. Preventive chemotherapy in human helminthiasis. Geneva: World Health Organization; 2006.
12. WHO. Lymphatic filariasis monitoring and epidemiological assessment of mass drug administration TAS. A manual for national elimination programmes. Geneva: World Health Organization; 2011.
13. WHO. Provisional strategy for interrupting lymphatic filariasis transmission in Loiasis-endemic countries. Lymphatic Filariasis and Loa. Geneva: World Health Organization; 2012.
14. WHO. Global programme to eliminate lymphatic filariasis. Lymphatic filariasis: practical entomology. A handbook for national elimination programmes. Geneva: World Health Organization; 2013.
15. UN. A new Global Partnership: The report of the high level panel of eminent persons on the post 2015 Development Agenda. New York, USA: United Nations; 2013.
16. Lancet Editorial. Neglected Tropical Diseases: becoming less neglected. Lancet; 2014;38:1269.
17. Adams J, Gurney KA, Pendlebury D. Neglected tropical diseases. Global research report. Leeds, UK: Thomson Reuters; 2012.
18. Samuels F, Rodriguez-Pose R. Why neglected tropical diseases matter. Working paper 03 July 2013. London, UK: Overseas Development Institute; 2013.
19. Molyneux DH. The 'Neglected Tropical Diseases': now a brand identity; responsibilities, context and promise. Parasit Vectors 2012;5:23.
20. Molyneux DH. Neglected tropical diseases. Community Eye Health 2013;26:21-4.
21. WHO Technical Report Series no. 972. Research Priorities for Helminth Infections. Geneva: World Health Organization; 2012.
22. WHO Technical Report Series 975. Research priorities for Chagas Disease, Human African Trypanosomiasis and Leishmaniasis. Geneva: World Health Organization; 2012.
23. WHO Technical Report Series No. 971. Research priorities for zoonoses and marginalized infections. Geneva: World Health Organization; 2012.
24. WHO. Research priorities for the environment, agriculture and infectious diseases of poverty. Geneva: World Health Organization; 2013.
25. WHO. The Global Report for Research on Infectious Diseases of Poverty WHO/TDR, 2012. Geneva: World Health Organization on behalf of the Special Programme for Research and Training in Tropical Diseases; 2012.
26. Boatin BA, Basanez MG, Prichard RK et al. A research agenda for helminth diseases of humans: towards control and elimination. PLoS Negl Trop Dis 2012;6:e1547.
27. Lustigman S, Prichard RK, Gazzinelli A et al. A research agenda for helminth diseases of humans: the problem of helminthiases. PLoS Negl Trop Dis 2012;6:e1582.
28. Basán{ogonek}ez MG, McCarthy JS, French MD et al. A research agenda for helminth diseases of humans: modelling for control and elimination. PLoS Negl Trop Dis 2012;6:e1548.
29. Molyneux D, Hallaj Z, Keusch GT et al. Zoonoses and marginalised infectious diseases of poverty: where do we stand? Parasit Vectors 2011;4:106.
30. Utzinger J. A research and development agenda for the control and elimination of human helminthiases. PLoS Negl Trop Dis 2012;6:e1646.
31. Bush S, Hopkins AD. Public-private partnerships in neglected tropical disease control: the role of nongovernmental organisations. Acta Trop 2011;Suppl 1:S169-72.
32. WHO. Accelerating work to overcome the global impact of neglected tropical diseases: a roadmap for implementation 2012. Geneva: World Health Organization; 2012. http://www.who.int/neglected_ diseases/NTD_RoadMap_2012_Fullversion.pdf [accessed 5 December 2012].
33. Liese BH, Schubert L. Official development assistance for health - how neglected are neglected tropical diseases? An analysis of health financing. Int Health 2009;1:141-7.
34. Bill & Melinda Gates Foundation. Dalberg report: analysis of the neglected tropical disease advocacy landscape 2013. Seattle, USA: Bill & Melinda Gates Foundation; 2013.
35. Fenwick A, Molyneux D, Nantulya V. Achieving the Millennium Development Goals. Lancet 2005;365:1029-30.
36. Conteh L, Engels T, Molyneux DH. Socioeconomic aspects of neglected tropical diseases. Lancet 2010;375:239-4.
37. Goldman AS, Guisinger VH, Aikins M et al. National mass drug administration costs for lymphatic filariasis elimination. PLoS Negl Trop Dis 2007;1:e67.
38. Leslie J, Garba A, Boubacar K et al. Neglected tropical diseases: comparison of the costs of integrated and vertical preventive chemotherapy treatment in Niger. Int Health 2013;5:78-84.
39. Seddoh A, Onyeze A, Gyapong JO et al. Towards an investment case for neglected tropical diseases. Lancet 2013;9908:1898-1955.
40. WHO. Global Atlas of Health Expenditure. Geneva: World Health Organization; 2012.
41. Gustavsen K, Hopkins A, Sauerbrey M. Onchocerciasis in the Americas: from arrival to (near) elimination. Parasit Vectors 2011;4:205.
42. Cupp E.W, Sauerbrey M, Richards F. Elimination of human onchocerciasis: historyof progress and current feasibility using ivermectin (Mectizan(w)) monotherapy. Acta Trop 2011;120(Suppl 1):S100-8.
43. World Bank. Essential Health for Africa: experience and lessons learnt. Washington DC, USA: The World Bank; 1994.
44. Nayyar GM, Bremen JG, Newton PN, Herrington J. Poor quality antimalarial drugs in southeast Asia and sub-Saharan Africa. Lancet Infect Dis 2012;12:488-96.
45. WHO Weekly Epidemiological Record. Rolling out and scaling up integrated preventive chemotherapy for selected neglected tropical diseases. Geneva: World Health Organization 2013;88:161-72.
46. WHO. Scientific and Technical Advisory Group. Geneva: World Health Organization; 2012.
47. Bockarie MJ, Kelly-Hope LA, Rebollo M, Molyneux DH. Preventive chemotherapy as a strategy for elimination of neglected tropical parasitic diseases: endgame challenges. Philos Trans R Soc B Biol Sci 2013;368:20120144.
48. Kelly-Hope LA, Molyneux DH, Bockarie MJ. Can malaria vector control accelerate the interruption of lymphatic filariasis transmission in Africa; capturing a window of opportunity? Parasit Vectors 2013,6:39.
49. Ngoumou P, Walsh JF, Mace JM. A rapid mapping technique for the prevalence and distribution of onchocerciasis: a Cameroon case study. Ann Trop Med Parasitol 1994;88:463-74.
50. Zouré HG, Wanji S, Noma M et al. The geographic distribution of Loa loa in Africa: results of large-scale implementation of the Rapid Assessment Procedure for Loiasis (RAPLOA). PLoS Negl Trop Dis 2011;5:e1210.
51. Gardon J, Gardon-Wendel M, Demanga ND et al. Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection. Lancet 1997;350:18-22.
52. Thomson MC, Obsomer V, Dunne M et al. Satellite mapping of Loa loa prevalence in relation to ivermectin use in west and central Africa. Lancet 2000;356:1077-8.
53. Thomson MC, Obsomer V, Kamgno J et al. Mapping the distribution of Loa loa in Cameroon in support of the African Programme for Onchocerciasis Control. Filaria J 2004;3:7.
54. Kelly-Hope LA, Thomas BC, Bockarie MJ, Molyneux DH. Lymphatic filariasis in the Democratic Republic of Congo; micro-stratification overlap mapping (MOM) as a prerequisite for control and surveillance. Parasit Vectors 2011;4:178.
55. Weil GJ, Lammie PJ, Weiss N. The ICT Filariasis Test: A rapid-format antigen test for diagnosis of bancroftian filariasis. Parasitol Today 1997;13:401-4.
56. Gyapong JO, Kyelem D, Kleinschmidt I et al. The use of spatial analysis in mapping the distribution of bancroftian filariasis in fourWest African countries. Ann Trop Med Parasitol 2002;96:695-705.
57. Onapa AW, Simonsen PE, Baehr I, Pederson EM. Rapid assessment of the geographical distribution of lymphatic filariasis in Uganda, by screening of schoolchildren for circulating filarial antigens, Ann Trop Med Parasitol 2005;99:141-53.
58. Molyneux DH. Filaria control and elimination: diagnostic, monitoring and surveillance needs. Trans R Soc Trop Med Hyg 2009;103:338-41.
59. Biswas G, Sankara DP, Agua-Agum J, Maiga A. Dracunculiasis (guinea worm disease): eradication without a drug or a vaccine. Philos Trans R Soc Lond B Biol Sci 2013;368:20120146.
60. Ruiz-Tiben E, Hopkins DR. Dracunculiasis (Guinea Worm disease) eradication. Adv Parasitol 2006;61:275-309.
61. Al-Awadi AR, Al-Kulhani A, Breman JG et al. Guinea worm (Dracunculiasis) eradication: update on progress and endgame challenges. Trans R Soc Trop Med Hyg 2014:108:249-51.
62. Homeida M, Braide E, Elhassan E et al. APOC's strategy of communitydirected treatment with ivermectin (CDTI) and its potential for providing additional health services to the poorest populations. African Programme for Onchocerciasis Control. Ann Trop Med Parasit 2002;96:(Suppl 1):S93-S104.
63. CDI Study Group. Community-directed interventions for priority health problems in Africa: results of a multicountry study. Bull World Health Organ 2010;88:509-18.
64. Eberhard ML, Ruiz-Tiben E, Hopkins DR et al. The peculiar epidemiology of dracunculiasis in Chad. Am J Trop Med Hyg 2014;90:61-70.
65. Alasaad S. War diseases revealed by social media: a massive leishmaniasis outbreak in the Syrian Spring. Parasit Vectors 2013;6:94.
66. Ross R. First progress report of the campaign against mosquitos in Sierra Leone. Liverpool School of Tropical Medicine. Memoir V Part 1. London, UK: University of Liverpool Press; 1901.
67. Morris MG. The persistence of toxicity in DDT impregnated hessian and its use on tsetse traps. Bull Ent Res 1950;41:259-88.
68. Lancien J. Campaign against sleeping sickness in South-West Uganda by trapping tsetse flies [in French]. Ann Soc Belge Med Trop 1991;71(Supp 1):35-47.
69. Van Nieuwenhoeve S, Schetcher PJ, Declerq J et al. Treatment of gambiense sleeping sickness in the Sudan with oral DFMO (DL-aplhadifluoromethylornithine), an inhibitor of ornithine decarboxylase; first field trial. Trans R Soc Trop Med Hyg 1985;79:692-8.
70. New RR, Chance ML, Thomas SC, Peters W. Antileishmanial activity of antimonials entrapped in liposomes. Nature 1978;272:55-6.
71. Jennings FW, Urquhart GM. The use of the 2 substituted 5-nitroimidazole, Fexinidazole (Hoe 239) in the treatment of chronic T. brucei infections in mice. Z Parasitenkd 1983;69:577-81.
72. Murray CJ, Vas T, Lozana R et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions,1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012,380:2197-23.
73. King CH, Dickman K, Tisch DJ. Reassessment of the cost of chronic helmintic infection: a meta-analysis of disability-related outcomes in endemic schistosomiasis. Lancet 2005;365:1561-9.
74. Litt E, Baker MC, Molyneux D. Neglected tropical diseases and mental health: a perspective on co-morbidity. Trends Parasitol 2012;28:195-201.
75. WHO. Mental health and development: targeting people with mental health conditions as a vulnerable group. Geneva: World Health Organization; 2010.
76. Weiss MG. Stigma and the social burden of neglected tropical diseases. PLoS Negl Trop Dis 2008;2:e237.
77. Ferrari AJ, Charlson FJ, Norman RE et al. Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010. PLoS Med 2013;10:e1001547.
78. Braich PS, Lala V, Hollands S, Almeida DR. Burden and depression in the caregivers of blind patients in India. Ophthalmology 2012;119:221-6.
79. Kjetland EF, Ndhlovu PD, Gomo E et al. Association between genital schistosomiasis and HIV in rural Zimbabwean women. AIDS 2006;20:593-600.
80. Kjetland EF, Leutscher PD, Ndhlovu PD. A review of female genital schistosomiasis. Trends Parasitol 2012;28:58-65.
81. Ndeffo Mbah ML, Poolman EM, Atkins KE et al. Potential costeffectiveness of schistosomiasis treatment for reducing HIV transmission in Africa-the case of Zimbabwean women. PLoS Negl Trop Dis 2013;7:e2346.
82. Secor WE. The effects of schistosomiasis on HIV/AIDS infection, progression and transmission. Curr Opin HIV AIDS 2012;7:254-9.
83. Hotez PJ, Fenwick A, Kjetland EF. Africa's 32 cents solution for HIV/ AIDS. PLoS Negl Trop Dis 2009;3:e430.
84. Stoever K, Molyneux D, Hotez P, Fenwick A. HIV, schistosomiasis, and girls. Lancet 2009;373:2025-6.
85. Mitja O, Hays R, Ipai A et al. Single-dose azithromycin versus benzyl penicillin for treatment of yaws in children in Papua New Guinea: an open label, non-inferiority, randomised trial. Lancet 2012;379:342-7.
86. Savioli L. Preventive anthelminthic chemotherapy-expanding the armamentarium. N Engl J Med 2014;370,665-6.
87. Durrheim DN, Wynd S, Liese B, Gyapong JO. Editorial: Lymphatic filariasis endemicity-an indicator of poverty? Trop Med Int Health 2004;9:843-5.
88. Stolk WA, ten Bosch QA, de Vlas SJ et al. Modeling the impact and costs of semi-annual mass drug administration for accelerated elimination of lymphatic filariasis. PLoS Negl Trop Dis 2014;7:e1984.
89. Katabawa M, Richards FR. Twice a year ivermectin for onchocerciasis:the time is now. Lancet Infect Dis 2014;14:373-4.